Source numbers link to evidence. [Inference] marks analytical judgment, including motion classifications and causal explanations. Public evidence does not establish every internal decision or metric.
Conceptual illustration of a clinical symbol, service counter, and notes sheet, presenting consumer care as an approachable subject rather than a specific treatment process.
- Company
- AIOS Medical · Consumer health services · aiosmedical.com
- Conversion motions
- [Inference] This research classifies AIOS Medical as Marketing Led and Human Led.
- AIOS Medical beachhead and target customer
- [Inference] Consumers seeking an established care pathway, with wider future ambitions stated by the company.
- Product and buying complexity
- [Inference] Consumer acquisition connects to clinical assessment, pharmacy operations and ongoing service.
- Market at entry
- [Unverified] This focused brief does not establish the full market conditions at first sale.
- Evidence
- Evidence brief · 1 linked source · research date · method and limitations
The ten-step Revenue Engine reading map
These links locate relevant evidence. A linked section does not imply every detail of the step is publicly established.
- Acquire Your First Customers: Founder Led Sales Read first customers
- Embrace GTM Experimentation Read experiments & lessons
- Understand Your GTM Motion Options Read GTM motion
- Pick Your GTM Motion Not established in this entry
- Generate a Lead Read GTM motion · Read experiments & lessons
- Turn Leads into Paying Customers Read GTM motion
- Retain and Grow Your Customers Read retain & expand
- Build Your GTM Team Not established in this entry
- Plan Your Tech Stack Read experiments & lessons
- Optimize and Scale Through Metrics Not established in this entry
AIOS Medical: Origin and evidence boundary
The first paid customer and founder closing sequence were not established in this focused evidence brief.
AIOS’s company-supplied YC profile identifies Richie Cartwright as founder and describes Bolt Pharmacy as its main UK brand. The profile says its initial growth focus is GLP-1 care and lists hiring for paid search, referrals and social content. Its longer-term autonomous-care ambitions are plans, not demonstrated regulatory or clinical outcomes. [1]
[1]AIOS Medical: Motion and buyer logic
[Inference] Consumers seeking an established care pathway, with wider future ambitions stated by the company.
[Inference] Consumer acquisition connects to clinical assessment, pharmacy operations and ongoing service.
[1]AIOS Medical: Retention and expansion hypothesis
[Inference] Geographic and product expansion depends on delivery capacity and relevant authorization; it is not simply adding software seats.
[Unverified] Individual CSM ownership, enablement conversion and renewal cohorts were not established in this brief.
AIOS Medical: Critical reading
[Inference] Separate revenue claims, treatment volume and future autonomy promises. Acquisition efficiency cannot establish clinical quality or sustainable service economics.
[Unverified] The inspected material does not establish failed-channel experiments or a complete causal account of growth.
AIOS Medical economics at a glance: Pricing is only half the story.
Exact current pricing was not verified in this brief.
[Inference] Geographic and product expansion depends on delivery capacity and relevant authorization; it is not simply adding software seats.
[Inference] Separate revenue claims, treatment volume and future autonomy promises. Acquisition efficiency cannot establish clinical quality or sustainable service economics.
Not publicly verified in this brief.
Not publicly verified in this brief.
The people in the AIOS Medical GTM story: People & capabilities.
Richie Cartwright
People identified in the sourceRichie Cartwright — founder named in the company’s YC profile.
See the source-backed account above; additional skills and training are not inferred as fact.
[1]AIOS Medical GTM: critical reading and analysis: Why it worked.
Where it breaks.
What worked—and why
[Inference] Separate revenue claims, treatment volume and future autonomy promises. Acquisition efficiency cannot establish clinical quality or sustainable service economics.
What did not work
No substantiated failed experiment established in the inspected evidence.
What could have been better
[Inference] Validate the proposed growth mechanism with paid conversion, implementation cost and retained customer outcomes.
What another founder can use
[Inference] Geographic and product expansion depends on delivery capacity and relevant authorization; it is not simply adding software seats.
AIOS Medical go-to-market FAQ: The questions that matter.
What does this case establish about AIOS Medical?
The inspected source supports the specific product, people or distribution facts in the origin section; a full chronological reconstruction remains incomplete. [1]
Is the full GTM history of AIOS Medical verified?
No. This is a focused evidence brief. The page distinguishes inspected claims from analytical hypotheses and lists the remaining gaps.
Which go-to-market motions is AIOS Medical classified under?
[Inference] This research classifies AIOS Medical as Marketing Led and Human Led. Motion labels describe routes across segments and periods, not measured revenue shares.
AIOS Medical sources and open questions: Follow the sources.
- Y Combinator company profile — inspected company evidence Y Combinator company profile · primary
Origin, product, team or current commercial route described in the source; narrower claims are attributed in the text.
What remains unverified
Evidence brief rather than a full historical GTM reconstruction.
First contracts, complete hiring sequence, pricing history, CAC and retention require further source verification.
No historical website screenshot or named account expansion is represented as verified.
No verified visual capture is attached to this entry. A current screenshot is not a substitute for a historical capture.
